enVVeno Medical Corp (NVNO) director receives 135,883 stock options

Rhea-AI Filing Summary

enVVeno Medical Corp director Matthew M. Jenusaitis reported receiving a grant of stock options in an SEC Form 4. On December 11, 2025, he was issued 135,883 stock options with an exercise price of $0.325 per share under the company’s Amended and Restated 2016 Omnibus Incentive Plan, as amended. These options relate to 135,883 shares of common stock and expire on December 11, 2035.

The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year. Following this grant, Jenusaitis beneficially owns 135,883 derivative securities, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenusaitis Matthew

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.325	12/11/2025		A		135,883		(1)	12/11/2035	Common Stock	135,883	$0	135,883	D

Explanation of Responses:

1. The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

	/s/ Matthew M. Jenusaitis	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did enVVeno Medical Corp (NVNO) report for its director?

The company reported that director Matthew M. Jenusaitis received a grant of 135,883 stock options to purchase enVVeno Medical Corp common stock.

How many stock options were granted to Matthew M. Jenusaitis and at what exercise price?

He was granted 135,883 stock options with a $0.325 per share exercise price, as disclosed in the Form 4.

When do the enVVeno Medical Corp (NVNO) director stock options vest?

The options are subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

What is the expiration date of the stock options granted to the enVVeno director?

The stock options granted to Matthew M. Jenusaitis expire on December 11, 2035, as stated in the filing.

How many derivative securities does Matthew M. Jenusaitis beneficially own after the reported transaction?

After the reported grant, he beneficially owns 135,883 derivative securities, corresponding to stock options, held in direct ownership.

Under what plan were the enVVeno Medical Corp (NVNO) stock options issued?

The options were issued under the issuer’s Amended and Restated 2016 Omnibus Incentive Plan, as amended, as explained in the response footnote.